Abstract Psoriasin (S100A7), originally identified in psoriasis, is a calcium-binding protein belonging to the multigenic S100 family. In high-grade ductal carcinoma in situ, psoriasin was identified as one of the most abundant transcripts. We have previously shown that psoriasin was induced by reactive oxygen species (ROS). Moreover, the downregulation of psoriasin by short hairpin RNA (shRNA) led to the reduced expression of vascular endothelial growth factor (VEGF) and inhibited tumor growth in vivo. The aim of the present study was to investigate whether psoriasin could have direct effects on endothelial cells. In this study we demonstrated that psoriasin increased VEGF expression in mammary epithelial cells. The treatment of endothelial cells with recombinant psoriasin increased proliferation comparable to that of recombinant VEGF protein. No change in proliferation was seen when endothelial cells were infected with psoriasin-expressing adenoviruses, suggesting that the proliferative effect of psoriasin was mediated by a specific receptor. Treatment with sRAGE, targeting the receptor for advanced glycation end products (RAGE), thus inhibited endothelial cell proliferation and tube formation enhanced by recombinant psoriasin. We showed that VEGF expression was not induced by hydrogen peroxide, when psoriasin was silenced by shRNA, which led to the hypothesis that psoriasin induces ROS. Indeed, psoriasin was shown to induce ROS in both endothelial and epithelial cells. Moreover, sRAGE inhibited the psoriasin-dependent generation of ROS in endothelial cells. Finally, treatment with antioxidant Bcl-2 protein abolished the effect of psoriasin on endothelial cell proliferation. Our data suggest that psoriasin expression in mammary epithelial cells leads to increased endothelial cell proliferation in a paracrine manner through RAGE. Psoriasin may therefore play a role in breast cancer progression by promoting oxidative stress response and angiogenesis.
Introduction
Tumor growth and metastasis are processes known to require neovascularization. As a result, angiogenesis has been intensively studied in the context of tumor growth. It is a complex, multistep process involving extracellular matrix remodeling, endothelial cell migration and proliferation, loop formation, capillary differentiation, anastomosis, and finally lumen development [1] . While the vasculature is usually quiescent in adult tissue and tightly regulated by the balance of pro-and anti-angiogenic signals in normal tissues, this process is often deregulated in cancer, which is important for neoplastic progression [2] . Among the growth factors involved in tumor angiogenesis, vascular endothelial growth factor (VEGF) has been identified as a leading pro-angiogenic candidate [3] . The production of VEGF is controlled through the cellular response to low oxygen levels (hypoxia) which activate the transcription of VEGF by increasing the formation of reactive oxygen species (ROS) [4, 5] . Moreover, VEGF mRNA levels were shown to be markedly increased in ductal carcinoma in situ (DCIS) and invasive breast carcinoma, compared with normal breast tissue [6, 7] .
In high-grade DCIS, which is an early clinical diagnosis of breast cancer, psoriasin (S100A7) was shown to be markedly upregulated [8, 9] . The expression of psoriasin was shown to correlate with features of poor prognosis, including estrogen receptor (ER) and progesterone receptor (PR) negativity, HER2 positivity, and the presence of lymphocytic infiltration [9] [10] [11] . Recently, we demonstrated that psoriasin correlates negatively with Intercellular adhesion molecule 1 (ICAM-1) and positively with Mucin1 (MUC1) [12] . Similar to VEGF, we have previously demonstrated that psoriasin is induced by ROS [13] . In addition, we have shown that the downregulation of endogenous psoriasin expression in the MDA-MB-468 breast cancer cell line by short hairpin RNA (shRNA) inhibited tumor growth in vivo. In accordance with these findings, we demonstrated the downregulation of VEGF in cells with reduced psoriasin levels [14] . These findings raised the hypothesis that psoriasin may increase tumor growth by promoting angiogenesis. In the present study, we investigated whether psoriasin could have direct effects on endothelial cells. In fact, we demonstrated that psoriasin was able to induce human endothelial cell proliferation through the receptor for advanced glycation end products (RAGE) and the generation of ROS. In addition, we demonstrated that psoriasin upregulated VEGF in epithelial cells. These findings prove a direct link between psoriasin and angiogenesis.
Materials and methods

Cell lines and culture conditions
The human immortalized normal breast epithelial cell line, MCF10A, and the human breast cancer cell line, MDA-MB-468, were obtained from American Type Culture Collection and cultured as previously described [9] . The human umbilical vein endothelial cells (HUVECs), obtained from Cascade Biologics, were grown in Medium 200 supplemented with LSGS. Neonatal human dermal microvascular endothelial cells (HMVEC-d), received as a gift from Dr Max Levin (Sahlgrenska University Hospital, Gothenburg, Sweden), were grown in endothelial growth medium (EGM) supplemented with EGM-2-MV (Lonza). A stable psoriasin-expressing cell line was established by infecting MCF10A cells with recombinant retrovirus overexpressing psoriasin [13] . The establishment of a stable clone with downregulated psoriasin expression was made by transfecting MCF10A with shRNA directed against human psoriasin, as previously described [14, 15] .
To examine the effect of intracellular psoriasin, MCF10A and HUVECs were infected with recombinant adenoviruses, as previously described [13] . Confluence culture was achieved by maintaining the cells in the confluent condition for 10 days. For suspension cultures, cells were plated into poly-2-hydroxy-ethylmethacrylate (polyHEMA) (Sigma-Aldrich, P-3932)-coated (10 mg/cm 2 in 95% ethanol) Petri dishes for 3 days. Hydrogen peroxide (H 2 O 2 ) (Sigma-Aldrich, H-1009) was added to a final concentration of 75-225 lM in HBSS and incubated for 1 h. The cells were then allowed to recover in regular medium for 5 days. Tumor necrosis factor-alpha (TNF-a) (Sigma-Aldrich, T-6674) was added to a final concentration of 5 ng/ml and incubated for 24 h. HUVECs were treated with various concentrations of recombinant psoriasin protein (Abnova) (0.15-10 lg/ml) or with recombinant VEGF protein (Invitrogen, PHC9394) (10 ng/ml) for 24 and 48 h. HUVECs were visualized using a Leica DMRXA Widefield Microscope (Leica Microsystems Inc.). To investigate the effect of RAGE on cell proliferation, HUVECs were treated with an anti-RAGE antibody (20 lg/ml for 3 h) (Millipore, MAB5328) or soluble RAGE (sRAGE) (50 ng/ml for 30 min) (R&D Systems, 1145-RG).
Purification of recombinant psoriasin protein
Psoriasin cDNA inserted into the pQE30 expression vector was kindly provided by Dr. Kornelia Polyak, at the DanaFarber Cancer Institute, in Boston. This vector was transformed into E. coli strain M15 (Qiagen, Inc.). The expression of recombinant 6X His-tagged psoriasin in E.coli, carrying pQE30-psoriasin, was induced with isopropyl b-D-1-thiogalactopyranoside (IPTG). The recombinant psoriasin protein was purified using NI-NTA agarose beads (Qiagen, Inc.) according to the manufacturer's instructions. Psoriasin was visualized by coomassie blue staining using a FluorChem 8000 camera (Alpha Innotech). Commercially available recombinant psoriasin protein (Abnova Corp., H00006278-P01) was also used in this study. Experiments were performed using commercially available recombinant psoriasin protein, if not otherwise stated.
RNA extraction, cDNA synthesis and quantitative Real-Time PCR (qRT-PCR) Total RNA was prepared using the RNeasy mini-kit (Qiagen, Inc., 74104). mRNA were converted to cDNA using SuperScript II RNase H-reverse Transcriptase (Invitrogen, 18.064-014) or Maxima First Strand cDNA Synthesis Kit 200 rxn (Fermentas, K1642), according to the manufacturer's instructions. The expression was analyzed with qRT-PCR, performed on a real-time 7500 HT sequence detection system (Applied Biosystems), with the SYBR green detection system (Applied Biosystems). The primers for psoriasin, VEGF, b-actin, and GAPDH, have been previously described [14, [16] [17] [18] . The primer set for RAGE is forward, 5 0 -ACGGCTGGTGTTCCCAATAA-3 0 , and reverse 5 0 -TGTTCCTTCACAGATACTCCCTTC-3 0 . GAPDH or b-actin was used as endogenous reference gene. The relative expression of psoriasin, VEGF, and RAGE was determined in relation to the expression in the control.
Western blotting
Western blotting as previously described [19] , and analyses were performed using anti-psoriasin (mouse-Ab) (Imgenex, IMG-409) and anti-GAPDH (rabbit-Ab) (Santa Cruz Biotechnology, sc-25778). Imaging analysis was performed using Alpha Ease FC software.
Flow cytometry
A total number of 3 9 10 5 cells were suspended in PBS and incubated with anti-RAGE (mouse-Ab) (Millipore, MAB5328) (1 lg/ml) for 60 min. Antibody binding was evidenced by FITC-conjugated secondary antibody (1:20) (goat anti-mouse) (Caltag Laboratories). Flow cytometry was performed to quantify the fluorescence intensity using the FACSAria (BD Biosiences).
Nitroblue tetrazolium (NBT) assay for the detection of ROS A NBT assay (Sigma-Aldrich, N5514) was performed as previously described [20] . The absorbance was measured at 630 nm using the Mithras LB940 instrument (Berthold Technologies).
Cell viability and proliferation
Cell proliferation was estimated using a CellTiter 96 Ò AQueous One Solution Cell proliferation assay (MTS) (Promega, G3582), according to the manufacturer's instructions. The activity of cellular dehydrogenases was measured by adding the tetrasodium salt MTS to the cells. Viable cells reduce the MTS tetrazolium salt into a soluble formazan product. The quantity of formazan was measured by the amount of absorbance at 490 nm using the Mithras LB940 Instrument (Berthold Technologies) and is directly proportional to the number of viable cells in proliferation. Moreover, cell proliferation was confirmed by trypan blue exclusion.
Tube formation assay
The formation of HUVECs in capillary-like structures was studied on Geltrex reduced growth factor basement membrane matrix (Invitrogen) in a 24-well plate according to manufacturer's instructions. Cells were visualized after 18 h of incubation using an Olympus IX51 inverted microscope and a PC-connected Olympus DP70 camera.
Statistical analysis
Data were analyzed for statistical significance by Student's t-test (one-tailed). P \ 0.05 was considered statistically significant. The values presented are an average of at least three independent experiments. Each independent experiment was performed at least in triplicate, if not otherwise stated.
Results
Psoriasin increases VEGF expression in mammary epithelial cells
To investigate the effect of the upregulation of psoriasin on the expression of VEGF, we utilized adenoviral vectormediated transient expression as well as retroviral vectormediated stable expression of psoriasin in the normal breast epithelial cell line, MCF10A. As shown in Fig. 1a , the upregulation of psoriasin at the mRNA level led to the significant upregulation of VEGF mRNA. A suspension culture of MCF10A cells, a condition we have previously demonstrated to induce high endogenous psoriasin levels [9] , also showed an increased expression of VEGF mRNA. This suggests that both exogenous and endogenous psoriasin expression is associated with increased VEGF expression in mammary epithelial cells.
Next, we suppressed the low endogenous level of psoriasin in MCF10A cells with shRNA targeting psoriasin mRNA. We confirmed the downregulation of psoriasin expression in the MCF10A psoriasin-shRNA cells compared with MCF10A control-shRNA (C-shRNA) cells after treatment with different concentrations of hydrogen peroxide (H 2 O 2 ), a stimulus known to induce high endogenous psoriasin levels (Fig. 1b) . As shown in Fig. 1c , H 2 O 2 led to the upregulation of VEGF mRNA in the MCF10A C-shRNA cells. In contrast, in MCF10A psoriasin-shRNA cells, the induction of VEGF mRNA was significantly reduced. Thus, psoriasin increases the expression of VEGF in mammary epithelial cells.
We investigated the expression of psoriasin in HUVECs using different stimuli that induce psoriasin in mammary epithelial cells. In contrast to the epithelial cells, HUVECs treated with H 2 O 2 , TNF-a or cultured in suspension or confluence condition did not express psoriasin (data not shown).
Extracellularly administered psoriasin triggers proliferation of endothelial cells
We and others have shown that psoriasin is secreted from epithelial cells [9, 20] . We hypothesized that psoriasin secreted from mammary epithelial cells may lead to endothelial cell proliferation. To address this, HUVECs were treated with various concentrations of recombinant psoriasin for 24 h. As shown in Fig. 2a , psoriasin significantly induced HUVEC proliferation, with the maximum effect at 0.15 lg/ ml, using the MTS assay. Extending the length of the treatment to 48 h did not increase HUVEC proliferation (data not shown). The effect of psoriasin was comparable to that of recombinant VEGF, used as a positive control for HUVEC proliferation (Fig. 2b, c) . The figure shows that both VEGF and psoriasin promoted HUVEC proliferation as compared with untreated control cells. The effect of psoriasin was also tested in HMVEC-d cells using the MTS assay. As shown in Fig. 2d , psoriasin significantly increased HMVEC-d proliferation as compared with the untreated control. The proliferation of HUVEC and HMVEC-d in response to psoriasin was confirmed using trypan blue exclusion (data not shown). These data confirm the effect of psoriasin on proliferation in two distinct endothelial cell types.
Extracellularly administered psoriasin triggers proliferation and tube formation of endothelial cells via RAGE
To further explore the proliferative effect of psoriasin in endothelial cells, HUVECs were treated with psoriasinexpressing adenovirus (Ad-Psoriasin-GFP), which led to the transient intracellular expression of psoriasin. As shown in Fig. 3a , no change in proliferation was seen when cells were infected with psoriasin-expressing adenoviruses. This finding led to the hypothesis that the proliferative effect of psoriasin on endothelial cells may be mediated by a specific receptor present on endothelial cells. RAGE belongs to the immunoglobulin superfamily and has been shown to be expressed on endothelial cells [21] and to be a putative receptor for several S100 proteins, including psoriasin [22, 23] . We examined whether RAGE was involved in the cellular responses to psoriasin in endothelial cells by using the specific inhibitory effect of soluble RAGE (sRAGE), which contains the ligand-binding domains, and an anti-RAGE antibody, which competes with the binding of ligands to RAGE. HUVECs were treated with sRAGE or anti-RAGE prior to psoriasin treatment. As shown in Fig. 3b , sRAGE significantly abrogated HUVEC proliferation in response to psoriasin treatment. Similarly, anti-RAGE treatment led to the decreased proliferation of HUVECs, although this effect did not reach statistical significance (data not shown). Furthermore, sRAGE reduced HUVEC tube formation, induced by recombinant psoriasin protein (Fig. 3c) . It is known that RAGE is expressed at low levels in normal tissues and becomes upregulated wherever its ligands accumulate. Extracellular psoriasin-induced RAGE expression at mRNA and protein level (Fig. 3d) . This results support the notion that RAGE is a receptor for psoriasin. In conclusion, our data suggest that RAGEmediated signaling is involved in psoriasin-induced endothelial cell proliferation and tube formation.
Psoriasin induces the proliferation of endothelial cells through the interaction with RAGE and ROS generation
It is known that ROS at low levels induces the proliferation of different cell types and specifically endothelial cells [24] . Both psoriasin [13] and VEGF [25] are induced by ROS. The finding that VEGF expression in epithelial cells is not induced by ROS when psoriasin is silenced by shRNA (Fig. 1c) led to the hypothesis that psoriasin induces ROS. To address this issue, HUVECs were exposed to recombinant psoriasin (0.15 lg/ml). A significant induction of ROS generation was observed (Fig. 4a) . We also demonstrated that recombinant VEGF induces ROS in HUVECs. Higher concentrations of recombinant psoriasin (0.5-10 lg/ml) showed a significant induction of ROS generation in the same range as 0.15 lg/ml psoriasin (data not shown). As demonstrated in Fig. 4b , the generation of ROS is significantly reduced when HUVECs are incubated with sRAGE prior to psoriasin treatment. These findings suggest that psoriasin induces the proliferation of endothelial cells through interaction with RAGE and increased levels of ROS. To investigate whether the proliferative effect of psoriasin on endothelial cells can be explained by this mechanism, HUVECs were pretreated with adenoviral Bcl-2 protein (Ad-Bcl-2-GFP), an antioxidant protein, followed by treatment with recombinant psoriasin. As shown in Fig. 4 c, Bcl-2 efficiently prevented the enhanced HUVEC proliferation, supporting the hypothesis that psoriasin-mediated ROS generation stimulates endothelial cell proliferation. Importantly, ROS generation was significantly reduced in MCF10A psoriasin-shRNA cells with downregulated psoriasin expression after H 2 O 2 treatment, supporting the hypothesis that psoriasin, previously known to be induced by ROS [13] , generates ROS.
Discussion
The progressive growth and metastasis of neoplasms, including breast cancer, depend on angiogenesis. VEGF is known as a multifunctional cytokine that plays a critical role in blood vessel formation including both vasculogenesis and angiogenesis [26] . VEGF promotes the induction of endothelial cell proliferation and capillary morphogenesis both in a paracrine mode, after its release by other cells, and in an autocrine manner in VEGF-producing endothelial cells [27] . In fact, the over-expression of VEGF has been regarded as a major factor underlying pathological angiogenesis in cancer, as well as in chronic inflammation, such as psoriasis [28] . We have previously shown that the downregulation of endogenous psoriasin expression in the MDA-MB-468 cell line by shRNA increased cell migration and invasion without influencing cell proliferation and survival in vitro but dramatically inhibited tumor growth in vivo, as assessed by tumor weight [14] . In line with these findings, we demonstrated an Untreated HUVECs were designed as 1 and treated HUVECs, from the same experiment, were normalized to this. The data are expressed as mean ± SD. In figure b, experiments were performed in duplicate. The P-values (* \ 0.05, ** \ 0.01) were calculated using a onetailed t-test, ns indicates not statistically significant bars compared to control upregulation of matrix metalloproteinase 13 (MMP13) and a downregulation of VEGF in cells with reduced psoriasin levels. Moreover, we demonstrated a statistically significant positive correlation between psoriasin expression and blood vessel density, determined by the immunohistochemical analysis of psoriasin and CD31, an endothelial cell-specific marker [14] . These findings raised the hypothesis that psoriasin may increase tumor growth in vivo by promoting angiogenesis. Correlating with this hypothesis, high-grade comedo DCIS, which frequently over-express psoriasin, is associated with increased VEGF levels and angiogenesis [29] . We have demonstrated a strong positive association between psoriasin and VEGF expression levels following the exogenous and endogenous upregulation of psoriasin in normal mammary epithelial cells. To investigate to which extent VEGF induction was influenced by the lack of endogenous psoriasin induction in MCF10A cells, we used shRNA specific for psoriasin. We showed that the downregulation of psoriasin reduced VEGF mRNA induction in MCF10A cells treated with H 2 O 2 . We and others have demonstrated that psoriasin may be secreted by but also located in the cytoplasm and the nucleus of the cells expressing it [9, 30] . To examine possible differences in extracellular and intracellular effects of psoriasin on endothelial cell proliferation, we treated endothelial cells with recombinant psoriasin protein and infected endothelial cells with psoriasin-expressing adenovirus. The proliferation of endothelial cells by extracellularly administered recombinant psoriasin was comparable to that seen for VEGF-stimulated cells. The lack of effect of intracellularly administered psoriasin led to the hypothesis that the proliferative effect may be mediated by a specific receptor.
RAGE is a multi-ligand receptor which recognizes ligands from diverse families, such as advanced glycation endproducts (AGEs), amphoterins, and S100/calgranulins [31] . RAGE transduces inflammatory responses and plays a role in the pathogenesis of several diseases including neurodegeneration, inflammation, and cancer [32, 33] . RAGE is able to bind a variety of structurally diverse ligands and the locations of RAGE upregulation tend to colocalize with molecules thought to bind to the receptor. Recently, RAGE was suggested as a putative receptor for some S100 proteins in the extracellular space [34] . S100A12 and S100B are well established as ligands of RAGE and, more recently, S100A8/A9 was shown to promote tumor cell growth via RAGE ligation [35] . Because of the common structural features and sequence homology among S100 proteins, we hypothesized that psoriasin was a putative ligand to RAGE in endothelial cells. It was recently shown that RAGE may mediate the psoriasin-mediated chemotaxis of leukocytes [22] . We demonstrated that, opposite to epithelial cells, psoriasin was neither expressed nor inducible in endothelial cells. We therefore predicted that psoriasin secreted from epithelial cells may interact with RAGE on the surface of endothelial cells, which may in turn induce endothelial cell proliferation and angiogenesis. To address this issue, we used a monoclonal antibody directed against the RAGE immunoglobulin domains (anti-RAGE) and sRAGE, a truncated form of the receptor spanning the extracellular domain of human RAGE, to inhibit the putative interaction between psoriasin and RAGE on the cell surface. Since sRAGE does not act on the receptor itself, but its ligands, treatment with sRAGE informs us of the consequences of reducing the bioavailability of the ligand as opposed to the consequences of preventing RAGE signal transduction [36] . By blocking RAGE-psoriasin interactions, a significant suppression of the psoriasin-induced increase in cell proliferation and tube formation were demonstrated. Based on the above data, we suggest that psoriasin stimulates endothelial cell proliferation and tube formation through RAGE. The identification of RAGE as a receptor for psoriasin raises the possibility of targeting psoriasin-mediated effects. Moreover, the interaction between secreted psoriasin and RAGE contributes to our understanding of RAGE in promoting tumor progression [33] . ROS have been reported to induce VEGF synthesis in various cell types. H 2 O 2 increased VEGF expression in keratinocytes [37] and in endothelial cells [38] . We have previously shown that psoriasin is induced by stress stimuli such as ROS [13] . Low levels of ROS may induce the proliferation of different cell types, specifically endothelial cells [39] . In HaCaT keratinocytes overexpression of S100A8 and S100A9 promoted NADPH oxidase activation followed by higher levels of ROS generation [40] . We hypothesized that psoriasin may induce low levels of ROS by a similar mechanism, leading to a further increase in ROS levels, VEGF expression, and cell growth. In fact, psoriasin was shown to induce ROS in endothelial cells. Moreover, when treating epithelial cells with H 2 O 2 , the level of ROS was reduced in cells with downregulated psoriasin demonstrating the role of psoriasin in ROS generation. It has previously been demonstrated that the interaction of RAGE with its ligands may generate ROS [41] . Interestingly, we found that sRAGE significantly eliminated ROS generation in endothelial cells after treatment with psoriasin, further suggesting that RAGE acts as a receptor for psoriasin.
To verify the role of psoriasin-dependent ROS production in endothelial cell proliferation by extracellular psoriasin protein, we cultured endothelial cells in the presence of Bcl-2, an antioxidant protein. We found that Bcl-2 significantly reduced the cell proliferation induced by psoriasin, supporting the hypothesis that endothelial cell proliferation by psoriasin is mediated by ROS.
ROS leads to a wide range of cellular functions, from proliferation to cell death, and these responses rely mostly on differences in the amount and duration of ROS production. Typically, low doses of ROS stimulate cell proliferation, whereas severe oxidative stress causes cell death [42] . It has been demonstrated that small amounts of ROS are produced after cell stimulation with a variety of hormones and growth factors, including VEGF, following binding to cell membrane receptors [43] . Low concentrations of ROS may even mimic the action of growth factors [44] . Interestingly, the increase in intracellular ROS levels Experiments were performed in duplicate. The P-values (* \ 0.05, ** \ 0.01) were calculated using a one-tailed t-test by extracellular psoriasin was in the same range as that previously demonstrated for S100B [45] .
Taken together, we have demonstrated that psoriasin contributes to the expression of ROS and VEGF and acts through RAGE to promote endothelial cell proliferation. A summary of the results is illustrated in Fig. 6 . The high expression of psoriasin in high-grade DCIS, which is likely to be hypoxic, with elevated levels of ROS and VEGF, makes psoriasin an interesting candidate marker for angiogenesis. Thus, psoriasin may play a role in breast cancer progression by promoting oxidative stress response and angiogenesis. Our data raise the possibility that psoriasin may be evaluated as a novel anti-angiogenic target in breast cancer. 
